Evidence map›Paper›PMID 28317077›Full record

ArticleJournal of nephrology2017

De novo cancer in patients on dialysis and after renal transplantation: north-western Italy, 1997-2012.

Valentina Mazzucotelli, Pierluca Piselli, Diana Verdirosi, Claudia Cimaglia, Giovanni Cancarini, Diego Serraino, Silvio Sandrini

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Observational
  17. Article
  18. Hypertensive nephropathy and cancer: Is it the hypertension, the nephropathy, or both?Journal of clinical hypertension (Greenwich, Conn.) · 2019
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Valentina MazzucotelliOperative Unit of Nephrology, ASST Spedali Civili, Brescia, Italy.
Pierluca PiselliClinical Epidemiology Unit - Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, via Portuense 292, 00149, Rome, Italy. pierluca.piselli@inmi.it.ORCID http://orcid.org/0000-0002-7342-0263
Diana VerdirosiUnit of Cancer Epidemiology, CRO Aviano National Cancer Institute, IRCCS, Aviano (PN), Italy.
Claudia CimagliaClinical Epidemiology Unit - Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, via Portuense 292, 00149, Rome, Italy.
Giovanni CancariniOperative Unit of Nephrology, ASST Spedali Civili, Brescia, Italy.
Diego SerrainoUnit of Cancer Epidemiology, CRO Aviano National Cancer Institute, IRCCS, Aviano (PN), Italy.
Silvio SandriniOperative Unit of Nephrology, ASST Spedali Civili, Brescia, Italy.
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITCentro di Riferimento Oncologico · ITIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · IT

Funding

Ministero della Salute Ricerca Corrente INMI "L. Spallanzani" IRCCSMinistero della Salute (IT) Ricerca Corrente - IRCCS CRO Aviano (PN)
6 · The paper itself

Abstract

backgroundKidney transplant recipients (KTR) are known to have a higher risk of cancer than the general population, especially of malignancies related to oncogenic viral infections. This study assessed the incidence of de novo malignancies (DNMs) in patients receiving kidney transplantation and in dialysis patients (DP) on the waiting list for transplantation at the same centre. The aim was to quantify the contribution of post-transplant immunosuppression to the underlying risk of developing a DNM in dialysis patients on the waiting list for kidney transplant.

methodsCancer incidence rates were computed using the Kaplan-Meier product-limit method. The number of DNMs observed in both groups was compared to the expected incidence in the general Italian population through calculation of the standardized incidence ratios (SIR) and their 95% confidence intervals (CI). To identify risk factors, incidence rate ratios (IRR) and 95% CIs were computed using Poisson regression analysis. The comparison of incidence rates between the two cohorts was also performed using age standardized incidence rates (ASR) and their ratio (age standardized rate ratio, ASRR).

resultsIn 4858 person-years (PYs) of observation, 75 out of 735 KTR were diagnosed with DNM: 57 solid neoplasms, 13 post-transplant lymphoproliferative disorders (PTLD), and 12 Kaposi sarcomas (KS). The overall incidence was 17.5 cases/10

conclusionOur study confirms the increased risk of cancer after transplantation and during dialysis, but showed that virus-related cancers only occur after post-transplant immunosuppression.

Indexed as

AdultAgedFemaleHumansImmune ToleranceKidney TransplantationMaleMiddle AgedNeoplasmsRenal DialysisRiskTime FactorsCancer riskDialysisImmunosuppressionKidney transplantationOncogenic viruses

Identifiers

PMID28317077
OpenAlexW2595376873

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.